LENVATINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY (R/R) SOLID TUMORS: RESULTS FROM THE SINGLE-ARM, PHASE 2 HOPSKIP STUDY

被引：0

作者：

Kang, Hyoung Jin ^{[1
]}

Abbou, Samuel ^{[2
]}

Mudry, Peter ^{[3
]}

Nicholls, Wayne ^{[4
]}

Kabickova, Edita ^{[5
,6
]}

Andre, Nicolas ^{[7
]}

Koh, Kyung-Nam ^{[8
]}

Casanova, Michela ^{[9
]}

Cefalo, Maria Giuseppina ^{[10
]}

Lombardi, Mercedes Garcia ^{[11
]}

Corradini, Nadege ^{[12
,13
]}

Naidu, Gita ^{[14
]}

Mckenzie, Jodi ^{[15
]}

Song, Yue ^{[16
]}

Singh, Rohini ^{[16
]}

Bidadi, Behzad ^{[16
]}

San Simon, Alba Rubio ^{[17
]}

机构：

[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Childrens Hosp,Dept Pediat, Seoul, South Korea

[2] Paris Saclay Univ, INSERM, U1015, Children & Adolescent Oncol Dept, Villejuif, France

[3] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic

[4] Childrens Hlth Queensland Hosp & Hlth Serv, Paediat Oncol, South Brisbane, Australia

[5] Charles Univ Prague, Prague, Czech Republic

[6] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic

[7] Hop Enfants La Timone, Smartc, Marseille, France

[8] Asan Med Ctr, Pediat, Seoul, South Korea

[9] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy

[10] Bambino Gesu Pediat Hosp, Oncohematol Cell & Gene Therapy, Rome, Italy

[11] Hosp Ninos Dr Ricardo Gutierrez, Oncol, Buenos Aires, DF, Argentina

[12] Ctr Leon Berard, Lyon, France

[13] Inst Hematol & Oncol Pediat, Oncol & Hematol, Lyon, France

[14] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Global Pediat Med, Johannesburg, South Africa

[15] Eisai Inc, Med Oncol, Nutley, NJ USA

[16] Merck & Co Inc, Med Oncol, Rahway, NJ USA

[17] Hosp Infantil Univ Nino Jesus, Dept Pediat Hematooncol, Madrid, Spain

来源：

PEDIATRIC BLOOD & CANCER | 2023年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O211

引用

页码：S119 / S119

页数：1

共 50 条

[21] Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M. Loeb
Ji Won Lee
Daniel A. Morgenstern
Yvan Samson
Anne Uyttebroeck
Chuhl Joo Lyu
An Van Damme
Karsten Nysom
Margaret E. Macy
Alexandra P. Zorzi
Julia Xiong
Petra Pollert
Ingrid Joerg
Yulia Vugmeyster
Mary Ruisi
Hyoung Jin Kang
Cancer Immunology, Immunotherapy, 2022, 71 : 2485 - 2495
[22] Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma
Shulman, David Stephen
Gustafson, Clay
Vo, Kieuhoa Tran
Fox, Elizabeth
Muscal, Jodi Ann
Supko, Jeffrey G.
Place, Andrew E.
Chi, Susan N.
Shusterman, Suzanne
Hanna, Gina
O'Brien, Jane
Ezrre, Suzanne
Carlowicz, Cecilia
London, Wendy B.
DuBois, Steven G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Sehn, Laurie H.
Hertzberg, Mark
Opat, Stephen
Herrera, Alex F.
Assouline, Sarit
Flowers, Christopher R.
Kim, Tae Min
McMillan, Andrew K.
Ozcan, Muhit
Safar, Violaine
Salles, Gilles
Hirata, Jamie
Yang, Annie
Musick, Lisa
Matasar, Matthew J.
BLOOD, 2022, 140 : 9464 - 9467
[24] Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia.
Hochberg, Jessica
Oesterheld, Javier E.
Militano, Olga
Klejmont, Liana
Harrison, Lauren
Nickerson, Berkley
Cairo, Mitchell S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY
Klisovic, R.
Winderlich, M.
Ambarkhane, S.
Jabbour, E.
HAEMATOLOGICA, 2017, 102 : 346 - 346
[26] Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
Liu, Chuanxu
Gao, Yan
Yu, Yang
Guo, Zhi
Zhao, Jun
Tao, Rong
Huang, Huiqiang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
O'Brien, Maureen M.
Alonzo, Todd A.
Cooper, Todd M.
Levine, John E.
Brown, Patrick A.
Slone, Tamra
August, Keith J.
Benettaib, Bouchra
Biserna, Noha
Poon, Jennifer
Patturajan, Meera
Chen, Nianhang
Simcock, Mathew
Zimmerman, Linda
Kolb, E. Anders
PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
[28] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song
Quanli Gao
Huilai Zhang
Lei Fan
Jianfeng Zhou
Dehui Zou
Wei Li
Haiyan Yang
Ting Liu
Quanshun Wang
Fangfang Lv
Haiyi Guo
Liudi Yang
Rebecca Elstrom
Jane Huang
William Novotny
Vivian Wei
Jun Zhu
Leukemia, 2020, 34 : 533 - 542
[29] Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/ Refractory (r/r) ALL
Sandhu, Karamjeet S.
Macias, Alan
Del Real, Marissa
Beltran, Asuscena L.
Kim, Young Sun
Zhang, Jianying
Palmer, Joycelynne
Robbins, Marjorie
Loomis, Reyna
Akhtari, Mojtaba
Aribi, Ahmed
Arslan, Shukaib
Salhotra, Amandeep
Mei, Matthew
Pourhassan, Hoda
Koller, Paul B.
Amanam, Idoroenyi
Agrawal, Vaibhav
Curtin, Peter T.
Spielberger, Ricardo
Pullarkat, Vinod A.
Aldoss, Ibrahim
Stewart, F. Mark
Smith, Eileen P.
Forman, Stephen J.
Stein, Anthony S.
Marcucci, Guido
Budde, L. Elizabeth
BLOOD, 2022, 140 : 8985 - 8986
[30] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Elstrom, Rebecca
Huang, Jane
Novotny, William
Wei, Vivian
Zhu, Jun
LEUKEMIA, 2020, 34 (02) : 533 - 542

← 1 2 3 4 5 →